Financings in Brief: Immunomedics
This article was originally published in The Gray Sheet
Executive Summary
Immunomedics: Completes $10 mil. private placement of 200,000 shares of non-dividend-paying convertible preferred stock "to several foreign investors," the firm states. The shares are convertible, at the discretion of the investors, into common stock during a "pre-determined period subject to extension." "The conversion price will be based on pre-determined discounts of up to 9-3/4% from the average market price per share over a 30-day trading period surrounding the dates conversion notices are received," Immunomedics says...
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.